---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-22-027812"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T12:46:04.841731+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vanda Q3 2022 revenue $65.3M (-7% YoY); net income $3.3M; narrows full-year guidance

## Summary
- Q3 total revenues $65.3M, down 7% from $70.1M; HETLIOZ sales $41.3M (-9%), Fanapt $24.0M (-2%).
- Net income $3.3M ($0.06 diluted EPS) vs $7.8M ($0.14) a year ago; first nine months net loss $0.6M.
- Full-year 2022 revenue guidance narrowed to $240-270M (from $240-280M); year-end cash forecast >$450M.
- Cash, cash equivalents and marketable securities $454.8M as of Sept 30, up $48.8M YoY.
- Pipeline: sNDA for HETLIOZ in insomnia expected by end-2022; NDA for tradipitant in gastroparesis expected H1 2023; Fanapt bipolar Phase III fully enrolled, results by end-2022.

## SEC filing metadata
- accession: 0001628280-22-027812
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/0001628280-22-027812-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/vnda-20221102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-22-027812
- JSON: https://secwatch.observer/filing/0001628280-22-027812.json
- Plain text: https://secwatch.observer/filing/0001628280-22-027812.txt

## Key facts
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported third quarter ended September 30, 2022 results: net income $3.3 million, EPS $0.06.
  - Period: third quarter ended September 30, 2022
  - Net income: $3.3 million
  - EPS: $0.06
  - Result: reported results
  source text: Net income was $3.3 million in the third quarter of 2022 compared to net income of $7.8 million in the third quarter of 2021. Diluted net income per share was $0.06 in the third quarter of 2022 compared to diluted net income per share of $0.14 in the third quarter of 2021.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/0001628280-22-027812-index.htm
- Earnings Releases
  Vanda Pharmaceuticals Inc. reported full year 2022 results: revenue $240 to $270 million. Guidance lowered.
  - Period: full year 2022
  - Revenue: $240 to $270 million
  - Guidance: lowered
  - Result: guidance update
  source text: Vanda is updating its 2022 financial guidance and expects to achieve the following financial objectives in 2022 : Full Year 2022 Financial Objectives Revised Full Year 2022 Guidance Prior Full Year 2022 Guidance Total revenues $240 to $270 million $240 to $280 million HETLIOZ ® net product sales $150 to $170 million $150 to $180 million Fanapt ® net product sales $90 to $100 million $90 to $100 million Year-end 2022 Cash Greater than $450 million Greater than $440 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1347178/000162828022027812/0001628280-22-027812-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.